CA3144185A1 - Yap inhibition for wound healing - Google Patents

Yap inhibition for wound healing Download PDF

Info

Publication number
CA3144185A1
CA3144185A1 CA3144185A CA3144185A CA3144185A1 CA 3144185 A1 CA3144185 A1 CA 3144185A1 CA 3144185 A CA3144185 A CA 3144185A CA 3144185 A CA3144185 A CA 3144185A CA 3144185 A1 CA3144185 A1 CA 3144185A1
Authority
CA
Canada
Prior art keywords
wound
enfs
days
yap
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3144185A
Other languages
English (en)
French (fr)
Inventor
Shamik MASCHARAK
Heather Elizabeth DESJARDINS-PARK
Mimi BORRELLI
Michael Francis DAVITT
Michael T. Longaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3144185A1 publication Critical patent/CA3144185A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3144185A 2019-07-26 2020-07-24 Yap inhibition for wound healing Pending CA3144185A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962879369P 2019-07-26 2019-07-26
US62/879,369 2019-07-26
PCT/US2020/043420 WO2021021607A2 (en) 2019-07-26 2020-07-24 Yap inhibition for wound healing

Publications (1)

Publication Number Publication Date
CA3144185A1 true CA3144185A1 (en) 2021-02-04

Family

ID=74229013

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3144185A Pending CA3144185A1 (en) 2019-07-26 2020-07-24 Yap inhibition for wound healing

Country Status (10)

Country Link
US (1) US20220313658A1 (enExample)
EP (1) EP4003334A4 (enExample)
JP (1) JP2022541572A (enExample)
KR (1) KR20220041154A (enExample)
CN (1) CN114401718A (enExample)
AU (1) AU2020320171B2 (enExample)
BR (1) BR112022001196A2 (enExample)
CA (1) CA3144185A1 (enExample)
IL (1) IL289923A (enExample)
WO (1) WO2021021607A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102550631B1 (ko) * 2021-03-16 2023-07-03 (주)파인헬스케어 인공지능을 이용한 욕창 단계 평가 및 치료 추천을 제공하는 장치 및 방법
CA3220398A1 (en) * 2021-07-30 2023-02-02 Geoffrey Gurtner Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same
US20240366565A1 (en) * 2021-09-09 2024-11-07 The Board Of Trustees Of The Leland Stanford Junior University Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury
CN114288474A (zh) * 2021-12-27 2022-04-08 湖北中部医疗科技有限公司 一种促毛囊再生用真皮层、人工皮肤及其制备方法
EP4514393A4 (en) * 2022-04-28 2026-04-01 Univ Leland Stanford Junior PIEZO-ELECTRIC INHIBITION FOR Wound Healing
CN116694089B (zh) * 2022-09-19 2024-03-26 广州贝奥吉因生物科技股份有限公司 一种用于抑制瘢痕的水凝胶及其制备方法和应用
CN116602265B (zh) * 2023-05-25 2024-05-14 北京工业大学 一种用于建立瘢痕疙瘩动物模型的智能控制系统及方法
CN117679393A (zh) * 2023-12-04 2024-03-12 中山大学附属第一医院 一种负载维替泊芬治疗增生性瘢痕的生物粘性纳米缓释颗粒
US20260115352A1 (en) 2024-10-28 2026-04-30 Cilag Gmbh International Verteporfin Containing Silicone Topical Skin Adhesive for Wound Closure and Reduced Scarring

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140984A1 (en) * 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
GB0823265D0 (en) * 2008-12-20 2009-01-28 Convatec Technologies Inc Antimicrobial Composition
DE102010009572A1 (de) * 2010-02-26 2011-09-01 Euroderm Gmbh Verfahren zum Begünstigen der Heilung von Hautwunden unter Verwendung der Zellen der Haarwurzelscheide, Präparat und Herstellverfahren
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US9655967B2 (en) * 2011-12-09 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of focal adhesion kinase for control of scar tissue formation
KR101385196B1 (ko) * 2012-05-17 2014-04-14 주식회사 유니크메디케어 광 조사를 이용한 광감각제―펩타이드를 유효성분으로 포함하는 발모 개선 또는 촉진용 조성물 및 이를 이용한 방법
US20150157584A1 (en) * 2012-06-11 2015-06-11 The J. David Gladstone Institutes Inhibitors of hippo-yap signaling pathway
EP2897689A4 (en) * 2012-09-24 2016-03-30 Cormatrix Cardiovascular Inc COMPOSITIONS AND METHODS OF TREATING ALOPEZIA
IL248468A0 (en) * 2016-10-13 2017-01-31 Technion Res & Dev Foundation Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing

Also Published As

Publication number Publication date
AU2020320171B2 (en) 2025-05-29
IL289923A (en) 2022-03-01
BR112022001196A2 (pt) 2022-03-15
US20220313658A1 (en) 2022-10-06
KR20220041154A (ko) 2022-03-31
EP4003334A2 (en) 2022-06-01
CN114401718A (zh) 2022-04-26
AU2020320171A1 (en) 2022-02-17
WO2021021607A3 (en) 2021-04-08
EP4003334A4 (en) 2023-08-16
WO2021021607A2 (en) 2021-02-04
JP2022541572A (ja) 2022-09-26

Similar Documents

Publication Publication Date Title
AU2020320171B2 (en) YAP inhibition for wound healing
AU2014281515B2 (en) Compositions and methods for treating skin
Bellei et al. Regenerative medicine-based treatment for vitiligo: an overview
Shi et al. Experimental study and clinical observations of autologous hair follicle cell transplants to treat stable vitiligo
US20150025452A1 (en) Methods for Modulating Hair Growth Using Truncated Laminin-511
EP3993764A1 (en) Method for preventing hair loss
Zhou et al. Pathogenesis and regenerative therapy in vitiligo and alopecia areata: Focus on hair follicle
TWI353849B (en) Methods and compositions for the promotion of hair
TWI614031B (zh) 防止皮膚老化相關症狀的醫藥組合物及其使用方法
HK40071204A (en) Yap inhibition for wound healing
Bai et al. ACE2 Inhibits Dermal Regeneration Through Ang II in Tissue Expansion
US20250195474A1 (en) Piezo Inhibition for Wound Healing
WO2023215294A1 (en) Complement pathway inhibition for wound healing
US20230355498A1 (en) Hair growth agent
WO2024248945A2 (en) Axl signaling pathway activator for wound healing
JP4212280B2 (ja) ヒト毛のｉｎｖｉｖｏ発毛誘導方法と、ヒト毛を有する非ヒト動物
Min Effect of carbon dioxide laser (10600nm) on hydroxyproline in mouse skin.
US20230390356A1 (en) Hair growth agent
Bernier et al. 0873 Modeling junctional epidermolysis bullosa using tissue-engineered skin substitutes
Nagalla et al. 0877 Activated wound phenotype and microbial dysbiosis are driven by AhR suppression in hidradenitis suppurativa tunnels
Linowiecka et al. 0875 Taxane chemotherapy induces premature aging and epigenetic changes in human hair follicles
Kosumi et al. 0872 Reserve transit-amplifying cells contribute to rapid tissue regeneration in nails
Aduba et al. 0876 Tsc2 deletion in mesenchymal cells improves distal digit regeneration
Sparks A Multimodal Approach to Augmenting Wound Healing: Progress Toward Dermal Regeneration in Mammals
HK40095475A (en) Hair growth agent

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220902

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240715

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240813

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241010

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241010

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250129

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250527

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250527

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250602

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250602

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260501

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260520

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260520

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260629

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260629